• Home
  • Archive
  • Media Kit
  • Contact Us
  • June 2, 2023

The Madison Times

The Paper That's More Than Black and White

  • News
    • Local News
    • National News
    • International News
    • Sports News
    • Education News
  • Columns
    • Columnists
    • Editorials
    • Letters to the Editor
    • Life Lessons with Alex Gee
  • Events
  • Health
  • Finance
  • Lifestyle
  • Classifieds
  • Community
    • Middle Spread
  • Milwaukee
EXCEPT WHERE INDICATED, THE OPINIONS EXPRESSED ON THIS PAGE ARE NOT NECESSARILY THOSE OF THE MADISON TIMES

Sharp Cuts to Research Funding Would Deprive Patients of Hope

January 4, 2020

By Mary Stabile

Congress is poised to pass two separate bills designed to bring down drug prices.

House Democrats and Senate Republicans are advancing bills that would set prices on prescription medicines, both directly and indirectly.

The House plan would allow the government to arbitrarily dictate the prices of 250 medicines, reducing drug companies’ revenues by an estimated $1 trillion over a decade.

The Senate’s plan would prohibit drug companies from raising prices faster than the rate of inflation and restructure Medicare’s prescription drug benefit in a way that effectively raises taxes on drug companies. All told, the Senate package would cost biopharmaceutical firms about $100 billion over a decade.

While both chambers have good intentions, the proposed pricing reforms would suppress medical research and, over time, deprive patients of new treatments.

Medical research is a high-risk, high-reward business. Most experimental drugs never make it out of the lab. Close to 90 percent of the ones that do ultimately fail in clinical trials. After accounting for these costly failures, companies spend $2.6 billion, on average, to bring one new medicine to patients.

Researchers rely on a few successful drugs to recoup their development costs and fund future projects. By making drug development far less lucrative, both bills would cause private sector research investment to plummet.

Some lawmakers acknowledge their plans would slash private research budgets. To offset that drop, they hope to reallocate some of the government’s savings to the National Institutes of Health.

But even with this new funding, the NIH won’t be able to replicate the work of scientists at private-sector research companies. The NIH mostly conducts early-stage research into specific diseases and molecules. It lacks the expertise, infrastructure, and funding to build on this research and develop treatments.

Large pharmaceutical companies invested more than $90 billion in U.S. research and development in 2016. Small biotech firms invested billions more. By comparison, the NIH’s annual research budget is less than $40 billion.

Millions of people suffer from debilitating conditions. Fifty million Americans suffer from rheumatoid arthritis, multiple sclerosis, and other diseases that cause a person’s immune system to attack healthy cells, organs, and tissue. Most of these ailments have no cure. And existing treatments often cause severe side effects.

These patients are counting on researchers to produce better treatments and cures. Thankfully, U.S. researchers are currently developing more than 4,500 new treatments for a variety of diseases, including type 1 diabetes, lupus, and heart disease.

By stifling this research, the bills would endanger patients’ health and lives. Let’s hope lawmakers reconsider before they snuff out patients’ hopes for a brighter, healthier future.

Mary Stabile is a patient advocate and healthcare expert who lives in the New York City area.

Share this:

  • Tweet
  • Email
  • Print

Popular Interests In This Article: Mary Stabile, Prescription Drug Prices

Read More - Related Articles

  • Seniors Across the Country Are Saving Millions of Dollars in Health Care Costs
  • Eli Lilly Heeds President Joe Biden’s Call to Cap the Price of Insulin
  • To Help Patients Save Money, Congress Needs to Tackle the Middlemen in Health Care
  • 340B Doesn’t Solve Health Inequities
  • “March In” Is Not the Answer





Connect With Us

Become Our Fan On Facebook
Find Us On Facebook


Follow Us On Twitter
Follow Us On Twitter

Editorials

Karma Chavez
Amanda Zhang
Julianne Malveaux
Benjamin Chavis
George Curry

Journalists

Jacklin Bolduan
Brianna Rae
Aarushi Agni
Rob Franklin
Claire Miller

Topics

Brown Girl Green $
Young Gifted & Black
Universally Speaking
Ask Progress
Civil Rights

Topics

Police Shooting
Police Brutality
Black Lives Matter
NAACP
Racism

Politicians

Barack Obama
Hillary Clinton
Gwen Moore
Paul Soglin
Scott Walker

Contact Us

The Madison Times
313 West Beltline Hwy
Suite 132
Madison, WI 53713
608-270-9470

Copyright © 2023 Courier Communications. All Rights Reserved.
We use third-party advertising companies to serve ads when you visit our website. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and to know your choices about not having this information used by these companies, click here.